Massachusetts-based biotechnology firm Biogen disclosed Wednesday it reached a $900 million agreement in principle to resolve a False Claims Act (FCA) lawsuit brought by a whistleblower alleging the payment of unlawful kickbacks to physicians.
Biogen discloses $900M agreement in whistleblower kickback suit
